Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.
France
ceftolozane-tazobactam
infectious disease
pneumonia
real-world evidence
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
28
08
2023
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
epublish
Résumé
This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings. This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T. A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%). This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population.
Sections du résumé
Background
UNASSIGNED
This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings.
Methods
UNASSIGNED
This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T.
Results
UNASSIGNED
A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%).
Conclusions
UNASSIGNED
This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population.
Identifiants
pubmed: 38390458
doi: 10.1093/ofid/ofae037
pii: ofae037
pmc: PMC10883286
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofae037Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. J.F.T. has received research funding from ad boards: MSD, PFIZER, GILEAD, MENARINI, BD, ASPEN, SHIONOGI; has reported research grants from MSD, PFIZER, THERMOFISCHER; and has been a speaker/advisor for MSD, PFIZER, BIOMERIEUX, QIAGEN, SHIONOGI, GILEAD, BD. B.C. has reported research funding from SANOFI, MSD, SHIONOGI; and has been a speaker/advisor for MSD, SANOFI, ADVANZ PHARMA, BIOMERIEUX. R.R. has been a speaker/advisor PFIZER, SHIONOGI; and has received research funding from ad boards from MSD. B.A., X.B., I.B., and C.M. were employees of MSD France at the time the study was conducted. D.B. has received research funding for ad boards from MSD. All other authors report no potential conflicts.